The 3rd Long-Acting Injectables and Implantables Conference (LAII 2020) in La Jolla yesterday and today is covering cutting edge developments in pharmaceutics, including TLC-ART’s newly funded Global Long-Acting Drug (GLAD) Project, transforming daily oral tenofovir-lamivudine-dolutegravir (TLD) pills into a long-acting injectable product for global access.
For more information see: http://drugdeliveryexperts.com/laii/